Secular trends in Klebsiella pneumoniae isolated in a tertiary-care hospital: Increasing prevalence and accelerated decline in antimicrobial susceptibility

Revista da Sociedade Brasileira de Medicina Tropical

Volumn 49, Issue 2, 2016, Pages 177-182

  Santana, Rodrigo de Carvalho ^a   Gaspar, Gilberto Gambero ^a   Vilar, Fernando Crivelenti ^a   Bellissimo Rodrigues, Fernando ^a   Martinez, Roberto ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Amikacin; Antimicrobial resistance; Carbapenem; Klebsiella pneumonia; Secular trends

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; CEFEPIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN; TIGECYCLINE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; ESCHERICHIA COLI; HEALTHCARE ASSOCIATED INFECTION; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREVALENCE; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; TERTIARY CARE CENTER; BRAZIL; DRUG EFFECTS; HUMAN; ISOLATION AND PURIFICATION; KLEBSIELLA INFECTION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; STATISTICS AND NUMERICAL DATA;

ANTI-BACTERIAL AGENTS; BRAZIL; DRUG RESISTANCE, BACTERIAL; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; PREVALENCE; RETROSPECTIVE STUDIES; TERTIARY CARE CENTERS;

EID: 84968817531     PISSN: 00378682     EISSN: None     Source Type: Journal    
DOI: 10.1590/0037-8682-0072-2016     Document Type: Article

References (28)

1. Broberg CA, Palacios M, Miller VL. Klebsiella: a long way to go towards understanding this enigmatic jet-setter. F1000 Prime Rep 2014; 6:64.
2. Saleem AF, Qamar FN, Shahzad H, Qadir M, Zaidi AK. Trends in antibiotic susceptibility and incidence of late-onset Klebsiella pneumoniae neonatal sepsis over a six-year period in a neonatal intensive care unit in Karachi, Pakistan. Int J Infect Dis 2013; 17:e961-e965.
3. Sanchez GV, Master RN, Clark RB, Fyyaz M, Duvvuri P, Ekta G, et al. Klebsiella pneumoniae antimicrobial drug resistance, United States, 1998-2010. Emerg Infect Dis 2013; 19:133-136.
4. Carvalhaes CG, Cayo R, Gales AC. Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae in the intensive care unit: a real challenge to physicians, scientific community, and society. Shock 2013; 39:32-37.
5. Patel G, Bonomo RA. "Stormy waters ahead": global emergence of carbapenemases. Front Microbiol 2013; 4:48.
6. Petrosillo N, Giannella M, Lewis R, Viale P. Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art. Expert Rev Anti Infect Ther 2013; 11:159-177.
7. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for antimicrobial susceptibility testing. Twentieth Informational Supplement M100-S20. Wayne, PA, USA: CLSI; 2010.
8. Bellissimo-Rodrigues F, Gomes ACF, Passos ADC, Achcar JA, Perdoná GSC, Martinez R. Clinical outcome and risk factors related to extended-spectrum beta-lactamase-producing Klebsiella spp. infection among hospitalized patients. Mem Inst Oswaldo Cruz 2006; 101:415-421.
9. Orsi GB, Giuliano S, Franchi C, Ciorba V, Protano C, Giordano A, et al. Changed epidemiology of ICU acquired bloodstream infections over 12 years in an Italian teaching hospital. Minerva Anestesiol 2015; 81:980-988.
10. Gupta A, Sharma S, Arora A, Gupta A. Changing trends of in vitro antimicrobial resistance patterns in blood isolates in a tertiary care hospital over a period of 4 years. Indian J Med Sci 2010; 64:485-492.
11. Yoon BI, Kim HS, Kim SD, Cho KJ, Kim SW, Ha US, et al. Changes in bacterial species and antibiotic sensitivity in intensive care unit: acquired urinary tract infection during 10 years interval (2001-2011). Urol J 2014; 11:1478-1484.
12. Andrade LN, Vitali L, Gaspar GG, Bellissimo-Rodrigues F, Martinez R, Darini AL. Expansion and evolution of a virulent, extensively drug-resistant (polymyxin B-resistant), QnrS1-, CTX-M-2-, and KPC-2-producing Klebsiella pneumoniae ST11 international high-risk clone. J Clin Microbiol 2014; 52:2530-2535.
13. de Cassia Andrade Melo R, de Barros EM, Loureiro NG, de Melo HR, Maciel MA, Souza Lopes AC. Presence of fimH, mrkD, and irp2 virulence genes in KPC-2-producing Klebsiella pneumoniae isolates in Recife-PE, Brazil. Curr Microbiol 2014; 69:824-831.
14. Sedlakova MH, Urbanek K, Vojtova V, Suchankova H, Imwensi P, Kolar M. Antibiotic consumption and its influence on the resistance in Enterobacteriaceae. BMC Res Notes 2014; 7:454.
15. Braykov NP, Eber MR, Klein EY, Morgan DJ, Laxminarayan R. Trends in resistance to carbapenems and third-generation cephalosporins among clinical isolates of Klebsiella pneumoniae in the United States, 1999-2010. Infect Control Hosp Epidemiol 2013; 34:259-268.
16. Sader HS, Farrell DJ, Flamm RK, Jones RN. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011). Diagn Microbiol Infect Dis 2014; 78:443-448.
17. Gales AC, Castanheira M, Jones RN, Sader HS. Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008-2010). Diagn Microbiol Infect Dis 2012; 73:354-360.
18. Sisto A, D'Ancona F, Meledandri M, Pantosti A, Rossolini GM, Raglio A, et al. Carbapenem non-susceptible Klebsiella pneumoniae from Micronet network hospitals, Italy, 2009 to 2012. Euro Surveill. 2012; 17:20247.
19. Huang CC, Chen YS, Toh HS, Lee YL, Liu YM, Ho CM, et al. Impact of revised CLSI breakpoints for susceptibility to third-generation cephalosporins and carbapenems among Enterobacteriaceae isolates in the Asia-Pacific region: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2002-2010. Int J Antimicrob Agents 2012; 40:S4-S10.
20. Liu PY, Shi ZY, Tung KC, Shyu CL, Chan KW, Liu JW, et al. Antimicrobial resistance to cefotaxime and ertapenem in Enterobacteriaceae: the effects of altering clinical breakpoints. J Infect Dev Ctries 2014; 8:289-296.
21. Nordmann P, Poirel L. The difficult-to-control spread of carbapenemase producers among Enterobacteriaceae worldwide. Clin Microbiol Infect 2014; 20:821-830.
22. Pereira PS, de Araujo CF, Seki LM, Zahner V, Carvalho-Assef AP, Asensi MD. Update of the molecular epidemiology of KPC-2-producing Klebsiella pneumoniae in Brazil: spread of clonal complex 11 (ST11, ST437 and ST340). J Antimicrob Chemother 2013; 68:312-316.
23. Bosso JA, Haines ML, Gomez J. Stable susceptibility to aminoglycosides in an age of low level, institutional use. Infec Dis Ther 2013; 2:209-215.
24. Bremmer DN, Clancy CJ, Press EG, Almaghrabi R, Chen L, Doi Y, et al. KPC-producing Klebsiella pneumoniae strains that harbor AAC(6')-Ib exhibit intermediate resistance to amikacin. Antimicrob Agents Chemother 2014; 58:7597-7600.
25. Papadimitriou-Olivgeris M, Christofidou M, Fligou F, Bartzavali C, Vrettos T, Filos KS, et al. The role of colonization pressure in the dissemination of colistin or tigecycline resistant KPC-producing Klebsiella pneumoniae in critically ill patients. Infection 2014; 42:883-890.
26. Pereira GH, Garcia DO, Mostardeiro M, Fanti KS, Levin AS. Outbreak of carbapenem-resistant Klebsiella pneumoniae: twoyear epidemiologic follow-up in a tertiary hospital. Mem Inst Oswaldo Cruz 2013; 108:113-115.
27. Lee J, Patel G, Huprikar S, Calfee DP, Jenkins SG. Decreased susceptibility to polymyxin B during treatment for carbapenemresistant Klebsiella pneumoniae infection. J Clin Microbiol 2009; 47:1611-1612.
28. Hawser SP, Bouchillon SK, Hackel M, Chen M, Kim EC. Trending 7 years of in vitro activity of tigecycline and comparators against Gram-positive and Gram-negative pathogens from the Asia-Pacific region: Tigecycline Evaluation Surveillance Trial (TEST) 2004-2010. Int J Antimicrob Agents 2012; 39:490-495.